# An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

> **NCT00492986** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 1150 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Nexavar (Sorafenib, BAY43-9006)

## Key facts

- **NCT ID:** NCT00492986
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 1150 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492986, "An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00492986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*